JP7478662B2 - カエサルピニア・スピノサ抽出物、カッパフィカス・アルベレッチー抽出物およびテオブロマカカオl豆の加水分解物を含む化粧品組成物 - Google Patents
カエサルピニア・スピノサ抽出物、カッパフィカス・アルベレッチー抽出物およびテオブロマカカオl豆の加水分解物を含む化粧品組成物 Download PDFInfo
- Publication number
- JP7478662B2 JP7478662B2 JP2020534847A JP2020534847A JP7478662B2 JP 7478662 B2 JP7478662 B2 JP 7478662B2 JP 2020534847 A JP2020534847 A JP 2020534847A JP 2020534847 A JP2020534847 A JP 2020534847A JP 7478662 B2 JP7478662 B2 JP 7478662B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- cosmetic composition
- cosmetic
- composition according
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 106
- 239000002537 cosmetic Substances 0.000 title claims description 68
- 239000000413 hydrolysate Substances 0.000 title claims description 36
- 244000299461 Theobroma cacao Species 0.000 title claims description 35
- 235000009470 Theobroma cacao Nutrition 0.000 title claims description 35
- 244000046052 Phaseolus vulgaris Species 0.000 title claims description 24
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title claims description 24
- 239000000284 extract Substances 0.000 title claims description 19
- 241001424341 Tara spinosa Species 0.000 title claims description 13
- 241001519517 Kappaphycus Species 0.000 title claims 2
- 229920000926 Galactomannan Polymers 0.000 claims description 27
- 239000004480 active ingredient Substances 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 21
- 230000001815 facial effect Effects 0.000 claims description 20
- 239000006041 probiotic Substances 0.000 claims description 19
- 235000018291 probiotics Nutrition 0.000 claims description 19
- 235000013406 prebiotics Nutrition 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 244000005714 skin microbiome Species 0.000 claims description 15
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- 230000008591 skin barrier function Effects 0.000 claims description 14
- 150000001720 carbohydrates Chemical class 0.000 claims description 13
- 210000002374 sebum Anatomy 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000000813 microbial effect Effects 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 238000005728 strengthening Methods 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 description 128
- 241000736262 Microbiota Species 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 15
- 206010021143 Hypoxia Diseases 0.000 description 14
- 244000005700 microbiome Species 0.000 description 14
- 239000000049 pigment Substances 0.000 description 13
- 230000000529 probiotic effect Effects 0.000 description 13
- 240000008886 Ceratonia siliqua Species 0.000 description 11
- 241001519524 Kappaphycus alvarezii Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 206010040844 Skin exfoliation Diseases 0.000 description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 230000001146 hypoxic effect Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 206010039792 Seborrhoea Diseases 0.000 description 9
- 230000035618 desquamation Effects 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 230000037312 oily skin Effects 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 8
- 241000186660 Lactobacillus Species 0.000 description 8
- 244000134540 Polymnia sonchifolia Species 0.000 description 8
- 235000003406 Polymnia sonchifolia Nutrition 0.000 description 8
- 229920001542 oligosaccharide Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- 239000004215 Carbon black (E152) Substances 0.000 description 7
- 229920001222 biopolymer Polymers 0.000 description 7
- 239000003086 colorant Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 229930195733 hydrocarbon Natural products 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 230000001052 transient effect Effects 0.000 description 6
- -1 β-defensins Chemical class 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 238000004040 coloring Methods 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000010445 mica Substances 0.000 description 5
- 229910052618 mica group Inorganic materials 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 description 4
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 244000187664 Nerium oleander Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 244000250129 Trigonella foenum graecum Species 0.000 description 4
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 244000005706 microflora Species 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 3
- 229920000310 Alpha glucan Polymers 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 3
- 229910000423 chromium oxide Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000013980 iron oxide Nutrition 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012860 organic pigment Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000037314 wound repair Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000298643 Cassia fistula Species 0.000 description 2
- 235000007631 Cassia fistula Nutrition 0.000 description 2
- 235000006693 Cassia laevigata Nutrition 0.000 description 2
- 244000277285 Cassia obtusifolia Species 0.000 description 2
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 2
- 244000201986 Cassia tora Species 0.000 description 2
- 235000014552 Cassia tora Nutrition 0.000 description 2
- 206010049047 Chapped lips Diseases 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- 241000196222 Codium fragile Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 description 2
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001428166 Eucheuma Species 0.000 description 2
- 241000940372 Eucheuma denticulatum Species 0.000 description 2
- 238000001134 F-test Methods 0.000 description 2
- 241001428241 Gelidium sesquipedale Species 0.000 description 2
- 241001491613 Gigartina skottsbergii Species 0.000 description 2
- 241000931143 Gleditsia sinensis Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 235000017367 Guainella Nutrition 0.000 description 2
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 2
- 241000016512 Kappaphycus striatus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 229920001273 Polyhydroxy acid Polymers 0.000 description 2
- 241000206639 Polysiphonia Species 0.000 description 2
- 241000522641 Senna Species 0.000 description 2
- 241001249696 Senna alexandrina Species 0.000 description 2
- 241000219784 Sophora Species 0.000 description 2
- 244000046101 Sophora japonica Species 0.000 description 2
- 235000010586 Sophora japonica Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- UHHXUPJJDHEMGX-UHFFFAOYSA-K azanium;manganese(3+);phosphonato phosphate Chemical compound [NH4+].[Mn+3].[O-]P([O-])(=O)OP([O-])([O-])=O UHHXUPJJDHEMGX-UHFFFAOYSA-K 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- 102000012265 beta-defensin Human genes 0.000 description 2
- 108050002883 beta-defensin Proteins 0.000 description 2
- 229940073609 bismuth oxychloride Drugs 0.000 description 2
- 235000012745 brilliant blue FCF Nutrition 0.000 description 2
- DGQLVPJVXFOQEV-JNVSTXMASA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-JNVSTXMASA-N 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 239000010903 husk Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940124513 senna glycoside Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- NDDLLTAIKYHPOD-ISLYRVAYSA-N (2e)-6-chloro-2-(6-chloro-4-methyl-3-oxo-1-benzothiophen-2-ylidene)-4-methyl-1-benzothiophen-3-one Chemical compound S/1C2=CC(Cl)=CC(C)=C2C(=O)C\1=C1/SC(C=C(Cl)C=C2C)=C2C1=O NDDLLTAIKYHPOD-ISLYRVAYSA-N 0.000 description 1
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- XLTMWFMRJZDFFD-UHFFFAOYSA-N 1-[(2-chloro-4-nitrophenyl)diazenyl]naphthalen-2-ol Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC1=CC=C([N+]([O-])=O)C=C1Cl XLTMWFMRJZDFFD-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AZXGXVQWEUFULR-UHFFFAOYSA-N 2',4',5',7'-tetrabromofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 AZXGXVQWEUFULR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- DSVUBXQDJGJGIC-UHFFFAOYSA-N 3',6'-dihydroxy-4',5'-diiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C(I)=C1OC1=C(I)C(O)=CC=C21 DSVUBXQDJGJGIC-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- ZDTNHRWWURISAA-UHFFFAOYSA-N 4',5'-dibromo-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C(Br)=C1OC1=C(Br)C(O)=CC=C21 ZDTNHRWWURISAA-UHFFFAOYSA-N 0.000 description 1
- NSWKKBKROCMOHA-UHFFFAOYSA-N 4-(naphthalen-1-yldiazenyl)naphthalen-1-ol Chemical compound Oc1ccc(N=Nc2cccc3ccccc23)c2ccccc12 NSWKKBKROCMOHA-UHFFFAOYSA-N 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 244000017106 Bixa orellana Species 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 101150014851 CLDN1 gene Proteins 0.000 description 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
- 240000009108 Chlorella vulgaris Species 0.000 description 1
- 235000007089 Chlorella vulgaris Nutrition 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 101150003986 DSG1 gene Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010045579 Desmoglein 1 Proteins 0.000 description 1
- 102100034579 Desmoglein-1 Human genes 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000642478 Homo sapiens Serpin B3 Proteins 0.000 description 1
- 101100208030 Homo sapiens TRPV3 gene Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 101150092727 KLF10 gene Proteins 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 108010065038 Keratin-10 Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001598113 Laminaria digitata Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150099954 PPBP gene Proteins 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100036383 Serpin B3 Human genes 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- 241000388430 Tara Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- CQPFMGBJSMSXLP-UHFFFAOYSA-M acid orange 7 Chemical compound [Na+].OC1=CC=C2C=CC=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 CQPFMGBJSMSXLP-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229940064062 alpha-glucan oligosaccharide Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 235000012665 annatto Nutrition 0.000 description 1
- 239000010362 annatto Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- POJOORKDYOPQLS-UHFFFAOYSA-L barium(2+) 5-chloro-2-[(2-hydroxynaphthalen-1-yl)diazenyl]-4-methylbenzenesulfonate Chemical compound [Ba+2].C1=C(Cl)C(C)=CC(N=NC=2C3=CC=CC=C3C=CC=2O)=C1S([O-])(=O)=O.C1=C(Cl)C(C)=CC(N=NC=2C3=CC=CC=C3C=CC=2O)=C1S([O-])(=O)=O POJOORKDYOPQLS-UHFFFAOYSA-L 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- DBZJJPROPLPMSN-UHFFFAOYSA-N bromoeosin Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 DBZJJPROPLPMSN-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006790 cellular biosynthetic process Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- PZTQVMXMKVTIRC-UHFFFAOYSA-L chembl2028348 Chemical compound [Ca+2].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 PZTQVMXMKVTIRC-UHFFFAOYSA-L 0.000 description 1
- ZLWLTDZLUVBSRJ-UHFFFAOYSA-K chembl2360149 Chemical compound [Na+].[Na+].[Na+].O=C1C(N=NC=2C=CC(=CC=2)S([O-])(=O)=O)=C(C(=O)[O-])NN1C1=CC=C(S([O-])(=O)=O)C=C1 ZLWLTDZLUVBSRJ-UHFFFAOYSA-K 0.000 description 1
- ONTQJDKFANPPKK-UHFFFAOYSA-L chembl3185981 Chemical compound [Na+].[Na+].CC1=CC(C)=C(S([O-])(=O)=O)C=C1N=NC1=CC(S([O-])(=O)=O)=C(C=CC=C2)C2=C1O ONTQJDKFANPPKK-UHFFFAOYSA-L 0.000 description 1
- 229940069826 chlorella vulgaris extract Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 229940075479 d & c red no. 27 Drugs 0.000 description 1
- 229940086624 d&c orange no. 10 Drugs 0.000 description 1
- 229940099449 d&c orange no. 4 Drugs 0.000 description 1
- 229940090962 d&c orange no. 5 Drugs 0.000 description 1
- 229940058010 d&c red no. 21 Drugs 0.000 description 1
- 229940056316 d&c red no. 28 Drugs 0.000 description 1
- 229940075484 d&c red no. 30 Drugs 0.000 description 1
- 229940075493 d&c red no. 6 Drugs 0.000 description 1
- 229940057946 d&c red no. 7 Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 1
- LQJVOKWHGUAUHK-UHFFFAOYSA-L disodium 5-amino-4-hydroxy-3-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].OC1=C2C(N)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1 LQJVOKWHGUAUHK-UHFFFAOYSA-L 0.000 description 1
- RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 229940057841 eosine yellowish Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940035901 lactobacillus sp Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- HGPXWXLYXNVULB-UHFFFAOYSA-M lithium stearate Chemical compound [Li+].CCCCCCCCCCCCCCCCCC([O-])=O HGPXWXLYXNVULB-UHFFFAOYSA-M 0.000 description 1
- 235000010187 litholrubine BK Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940105112 magnesium myristate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- DMRBHZWQMKSQGR-UHFFFAOYSA-L magnesium;tetradecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O DMRBHZWQMKSQGR-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000011146 organic particle Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- ZYIBVBKZZZDFOY-UHFFFAOYSA-N phloxine O Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 ZYIBVBKZZZDFOY-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- VIHIKSJKXIMMLV-FZTHFCCHSA-M potassium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] phosphate Chemical compound [K+].C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OP([O-])(=O)OC1=C(O)[C@@H]([C@@H](O)CO)OC1=O VIHIKSJKXIMMLV-FZTHFCCHSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- TVRGPOFMYCMNRB-UHFFFAOYSA-N quinizarine green ss Chemical compound C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1 TVRGPOFMYCMNRB-UHFFFAOYSA-N 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940094944 saccharide isomerate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037070 skin defense Effects 0.000 description 1
- 230000005995 skin dysfunction Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- LJFWQNJLLOFIJK-UHFFFAOYSA-N solvent violet 13 Chemical compound C1=CC(C)=CC=C1NC1=CC=C(O)C2=C1C(=O)C1=CC=CC=C1C2=O LJFWQNJLLOFIJK-UHFFFAOYSA-N 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229940098697 zinc laurate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GPYYEEJOMCKTPR-UHFFFAOYSA-L zinc;dodecanoate Chemical compound [Zn+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O GPYYEEJOMCKTPR-UHFFFAOYSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
Description
-一過性菌叢:一過性菌叢は、環境から腐敗した有機物を餌とする腐生菌と呼ばれる、大抵は無害な真菌、ウイルスおよび細菌からなる。この菌叢は恒久的なものではなく、行われる活動や周辺条件の変化、個体がこれらの条件に露出されることによって日中に変化する。最も一般的な一過性菌叢の種としては、スタフィルオコックス・アウロイス(Staphylococcus aureus)、エスケリキア・コリ(Escherichia coli)、シュードモナス・アエルギノーサ(Pseudomonas aeruginosa)およびバチルスの種である。
-常在菌叢:常在菌叢は共生菌からなり、すなわちそれらの宿主のおかげで何の損傷も与えずに生きている。この菌叢の構成は固定されており、妨害された後、同じ構成に自発的に再形成される。これらの微生物(グラム陽性細菌、グラム陰性細菌など)は表皮に生息しており、主に角質層の上層ならびに汗腺や毛嚢脂腺の毛包(pilosebaceous follicle)の管、爪や毛髪のような表皮付属器で見つかられる。
-細胞凝集の構成要素を形成し、それによって表皮の抵抗力を形成するタンパク質であるデスモグレイン-1の形成を減少させることにより(Straseski J et al. Wound Repair Regen. 2009; 17(4): 606-616)
-また水分を表皮に輸送し、皮膚に水分補給するタンパク質であるアクアポリン3の形成を減少させることにより(Straseski J et al. Wound Repair Regen. 2009; 17(4): 606-616)
-皮膚の構成成分や細胞を変化させる活性酸素種(ROS)の産生を刺激することにより(Nys K et al. Free Radic Biol Med. 2012;52(6):1111-20)
-ケラチン10などの分化ケラチンの形成を抑制することにより(Straseski J et al. Wound Repair Regen. 2009; 17(4): 606-616)、および/または
-マトリックスメタロプロテアーゼまたはMMPの存在を増加させることにより(Xia YP et al. J. Invest. Dermatol. 2001; 116: 50-56)、コラーゲンなどの皮膚の構成成分を壊し、皮膚密集度や弾力に影響を与え、その結果として、毛穴の開きおよび細かい線やしわの形成をもたらし得る。
-皮膚バリアの強化や皮脂産生の制御などが可能な皮膚状態を提供することで、微生物叢およびその多様性を維持することにより、
-表皮の凝集を高め、皮膚の抵抗力を強化することにより、
-皮膚バリアの形成を刺激し、皮膚に十分な水分を維持することにより、
-皮膚の活性酸素種を無毒化することにより、
-MMPの形成を抑制することにより、および/または
-低酸素症から皮膚細胞を保護する低酸素症誘導因子またはHIFの形成を刺激することにより。
a)モル質量が5~630kDa、好ましくは5~120kDa、より好ましくは8~80kDaのガラクトマンナンおよびモル質量が7~3000kDa、好ましくは7~1100kDa、より好ましくは8~200kDaの架橋硫酸化ガラクタンからなる化粧剤、ならびに
b)テオブロマカカオL豆の加水分解物。
本発明によれば、「ケラチン物質」とは、皮膚、粘膜(特に唇)および毛髪および爪を意味する。特定の実施態様によれば、組成物は、皮膚、唇または毛髪および爪、好ましくは皮膚への局所適用を目的とする。
したがって、本発明の第一の目的は、生理学的に許容できる媒体中に少なくとも以下の物質を含む化粧品組成物である:
a)モル質量が5~630kDa、好ましくは5~120kDa、より好ましくは8~80kDaのガラクトマンナンおよびモル質量が7~3000kDa、好ましくは7~1100kDa、より好ましくは8~200kDaの架橋硫酸化ガラクタンからなる化粧剤、ならびに
(b)テオブロマカカオL豆の加水分解物。
本発明の意味での化粧剤は、バイオポリマー、すなわち化学合成によって得られる植物原料物質由来のポリマーからなる。
-モル質量が5~630kDaのガラクトマンナン、および
-モル質量が7~3000kDaの架橋硫酸化ガラクタンからなる。
-平均モル質量が5~120kDaのガラクトマンナンおよび平均モル質量が7~1100kDaの架橋硫酸化ガラクタンからなる。
-天然ガラクトマンナン粉末または天然硫酸化ガラクタンそれぞれの水への溶解化
-化学的または酵素的ルートによる加水分解
-不溶性相を除去するための、可溶性相または不溶性相の分離
-規定の分子量のガラクトマンナンの膜濾過による選択
本発明によるテオブロマカカオL.の加水分解物は、主にペプチドおよびサッカライドを含む、テオブロマカカオL豆のペプチドおよびサッカライド加水分解物である。用語「主にペプチドおよびサッカライド」とは、50%を超える量、好ましくは60%を超える量、好ましくは70%を超える量、最大90%(重量/重量)のペプチドおよびサッカライドの乾燥物質、好ましくは90%の重量の乾燥物質を意味する。
a)挽いたテオブロマカカオL豆を水相中に分散させ;
b)工程a)で得られる水分散液を酵素処理し;
c)固液分離により酵素加水分解物を回収し;
d)超ナノ濾過により加水分解物精製し、その後、場合により
e)工程d)で得られる加水分解物を凍結乾燥させる。
「プレバイオティクス」とは、ヒトの健康に有益な腸のプロバイオティクス菌株(ラクトバシリ(lactobacilli)、ビフィズス菌など)およびほかの細菌の菌株の増殖や活性を調節する性質を有する非生物性食品成分を意味する。プレバイオティクスは、一般に果物や植物、蜂蜜などに自然に存在する抽出可能な単糖類、二糖類またはオリゴ糖類である。他は、多糖(例えばオリゴフルクトースまたはフルクト-オリゴ糖、略称FOS)の加水分解により工業的に生産するか、またはラクトースなどの二糖類に転移活性を有するラクターゼなどの酵素の作用を受けさせ、トランス-ガラクト-オリゴ糖(TOS)を生成するか、もしくは化学異性化反応によりラクツロースを生成することによって合成する。現在、プレバイオティクス効果が認められているものとしては、トランス-ガラクトオリゴ糖(GOS)やイヌリン型フルクタン類が挙げられる。
ECOSKIN(R)の組成物は、70%のα-グルカンオリゴ糖、19%のヤーコン(Polymnia Sonchifolia)根の搾汁、10%のマルトデキストリン、1%のラクトバチルス(Lactobacillus)(90%の活性成分に相当)である。
本発明による組成物は、より詳しくは、ケラチン物質、特に皮膚への局所適用を目的とする。
本発明の目的のために、色材とは、適切な化粧品媒体中に十分な量で製剤化される場合に、有色光学効果をもたらすことができる化合物として定義される。
-皮膚の微生物叢の生物多様性および恒常性(活性成分であるActibiome(C)(水および海水およびグリセリンおよびラミナリア・ディギタータ(Laminaria digitata)抽出物およびクロレラ・ブルガリス(Chlorella vulgaris)抽出物および異性化糖(saccharide isomerate)およびフェノキシエタノールおよびエチルヘキシルグリセリン)のように、ストレスの期間によってあらかじめ低下された皮膚のpHを再調整することにより);
-細胞再生(酸性のpHで「ピーリング」効果がある活性成分の単独または組み合わせにより):
・化学的手段(αヒドロキシ酸(AHA)(グリコール酸、乳酸、クエン酸...)、βヒドロキシ酸(BHA)(サリチル酸)、ポリヒドロキシ酸(PHA)(グルコノラクトン)など)により;
・生物学的手段(Exfolactive C EL PX(C)(オプンティア・コチネリフェラ(Opuntia coccinellifera))、DERMOCH DP(C)(Chlorella vulgaris)、ALGOWHITE(C)(アスコフィラム・ノドサム(Ascophyllum nodosum)など)により
・酵素経路(MELACLEAR(C)(グルコン酸、スティラインズ))により;
-顔の肌の再生または再活性化(輝き)(以下の活性成分を用いて):
・レチノールのような平滑化(ビタミンA様)
・メラニン生成に作用することによるライトナー(ビタミンC誘導体)
・エネルギー付与剤(energizer)(栄養素および/または抗酸化剤であるビタミンCおよびビタミンE(SEPIVITAL(C)(リン酸アスコルビルトコフェロールカリウム)など)など);
-皮脂産生の減少(セボトラッピング剤(sebo-trapping agent)(クレイ)または、グルコン酸亜鉛(Mineralis GU/Zn)およびアボカドリポフィル抽出物(5αavocuta)などの皮脂調節活性剤(sebo-regulating active agent)を用いて);
-外部からの侵入(汚染、ブルーライト、化学的または鉱物フィルターを使用および/または反射粒子を拡散させるUV、またはこれらの混合物)からの保護。
これらの活性成分を単独または組み合わせて用いた転写効果に関する研究は、TaqMan Low Density Array(TLDA)技術を用いて行った。この技術のおかげで、正常なヒト角化細胞(ケラチン生成細胞)の処置に応じた、特定のタンパク質をコードする遺伝子の発現の変調が研究され、これは、上記活性成分の単独または組み合わせでの遺伝子発現のマッピングを可能にした。
用いられた細胞:正常ヒト表皮角化細胞
培地:HKGS(ヒト-角化細胞-増殖-サプリメント)が補充されたEpiLife(R)
細胞の皮膚由来:腹部採取、女性、47歳
研究モデル:TaqMan Low Density Array (TLDA)技術
化合物での細胞の処理:24時間
試験化合物:
・0.05%のBLUMILIGHTTM(ブチレングリコールおよび水およびテオブロマカカオ(ココア)種子抽出物)。
・0.25%のFILMEXEL(R)(カエサルピニア・スピノサ(CAESALPINIA SPINOSA)抽出物およびカッパフィカス・アルベレッチー(Kappaphycus alvarezii)抽出物および水)。
・0.05%のBLUMILIGHTTM+0.25%のFILMEXEL(R)
選択される実験条件は以下の通りである:
-各試験は、3回実施する(未処理の3回、同一条件で処理される3回);
-Fischer F-検定は、最初に2つのデータ行列を比較することによって適用する。値がα=0.05より大きい場合、スチューデントのt-検定の分散は2で、FischerのF-検定がα= 0.05より小さい場合、分散は3になる。
-保持される転写変動(有意)は、スチューデントのt検定においてα(またはp)=0.05未満またはそれに等しく対応するものになる。抑制は淡い灰色で示し、刺激は濃い灰色(下記参照)で示し、白色の背景は、有意でない変動、すなわちスチューデントのt検定においてα(またはp)=0.05より大きく対応するものを示す。
-「測定されていない」の表示「ND」は、遺伝子の転写活性が小さすぎて、使用されるTLDA方法により定量化することができないことを意味する。
-SERPINA3、SERPINB3などのプロテアーゼ阻害剤の遺伝子の活性化を介してこれらのタンパク質構造の劣化を防止することにより、毛穴の収れん効果および皮膚の起伏(relief)の充填において、その維持に関与する皮膚のタンパク質構造の完全性を促進させ、
-コルネオデスモソーム(corneodesmosome)の形成に関与するDSG1遺伝子の転写活性を刺激することにより、表皮の機械的な抵抗力を強化し(細胞間をつなぐタンパク質構造)、
-細胞間水分の通過を制限し(不感水分喪失)、表皮脂質を皮膚表面に維持する細胞間密着結合の形成に関与するCLDN1遺伝子の転写活性刺激することにより、皮膚バリア性能を改善し、
-特に表皮ケラチン生成細胞の分化に関与するKLF10遺伝子の転写活性を刺激し、創傷治癒および血管新生に関与するPPBP遺伝子(別名CXCL7)の転写活性を刺激することにより、表皮の適切な発育を促進させ、
-表皮の脆弱性(細胞アポトーシス)にも関与するTRPV3遺伝子の転写活性を抑制することにより、表皮の感覚的要素、特に炎症に起因する不快感の感覚を重くする感覚的要素を調整し、
-殺菌性および抗真菌性抗菌サイトカインであるCXCL7遺伝子の転写活性を刺激することにより、微生物叢の皮膚制御を向上させる。
Claims (17)
- 生理学的に許容できる媒体中に少なくとも以下の物質を含む化粧品組成物:
a)モル質量が5~630kDaの加水分解されたガラクトマンナンを含むカエサルピニア・スピノサ抽出物、およびモル質量が7~3000kDaの加水分解された架橋硫酸化ガラクタンを含むカッパフィカス・アルベレッチー抽出物からなる化粧剤、ならびに
b)テオブロマカカオL豆の加水分解物。 - ガラクトマンナンのモル質量が5~120kDaであり、架橋硫酸化ガラクタンのモル質量が7~1100kDaであることを特徴とする、請求項1に記載の化粧品組成物。
- ガラクトマンナンのモル質量が8~80kDaであり、架橋硫酸化ガラクタンのモル質量が8~200kDaであることを特徴とする、請求項2に記載の化粧品組成物。
- 化粧剤a)が、組成物総重量に対して0.01重量%~2重量%の範囲の含有量で組成物中に存在することを特徴とする、請求項1~3のいずれか一項に記載の化粧品組成物。
- 化粧剤a)が、組成物総重量に対して0.4重量%~0.8重量%の範囲の含有量で組成物中に存在することを特徴とする、請求項4に記載の化粧品組成物。
- テオブロマカカオL豆の加水分解物がテオブロマカカオL豆加水分解物のペプチドおよびサッカライドであることを特徴とする、請求項1~5のいずれか一項に記載の化粧品組成物。
- ペプチドおよびサッカライドが、200Da~10kDaの分子量を有することを特徴とする、請求項1~6のいずれか一項に記載の化粧品組成物。
- テオブロマカカオL豆の加水分解物が、組成物総重量に対して0.0005重量%~0.025重量%の範囲の活性成分の含有量で組成物中に存在することを特徴とする、請求項1~7のいずれか一項に記載の化粧品組成物。
- テオブロマカカオL豆の加水分解物が、組成物総重量に対して0.001重量%~0.01重量%の範囲の活性成分の含有量で組成物中に存在することを特徴とする、請求項8に記載の化粧品組成物。
- さらにプレバイオティクスおよびプロバイオティクスを含むことを特徴とする、請求項1~9のいずれか一項に記載の化粧品組成物。
- 皮膚、唇または眼のためのケア製品および/またはメイクアップ製品の形態であることを特徴とする、請求項1~10のいずれか一項に記載の化粧品組成物。
- 顔の肌のためのケア製品および/またはメイクアップ製品の形態であることを特徴とする、請求項11に記載の化粧品組成物。
- ケラチン物質をケアおよび/またはメイクアップするための化粧方法であって、請求項1~12のいずれか一項に記載の化粧品組成物を、該ケラチン物質に少なくとも適用することを含む方法。
- 化粧品組成物が、顔の肌のための化粧品組成物であることを特徴とする、請求項13に記載のケラチン物質をケアおよび/またはメイクアップするための化粧方法。
- 皮膚生態系を維持すること、および/または皮膚微生物叢のバランス、微生物多様性を維持すること、皮膚バリアおよび皮膚のハイドロリピッドフィルムを強化すること、ストレスに対する皮膚の完全性および抵抗力を改善すること、を目的とする、請求項13または14に記載のケラチン物質をケアおよび/またはメイクアップするための化粧方法。
- 高脂漏と関連している障害の処置および/または減少に使用するための、請求項1~12のいずれか一項に記載の化粧品組成物。
- 皮脂依存性炎症および/または細菌増殖と関連している障害の処置および/または減少に使用するための、請求項1~12のいずれか一項に記載の化粧品組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1763141A FR3075621B1 (fr) | 2017-12-22 | 2017-12-22 | Composition cosmetique comprenant un extrait de caesalpinia spinosa, un extrait de kappaphycus alvarezii, et un hydrolysat de feves de theobroma cacao l |
FR1763141 | 2017-12-22 | ||
PCT/FR2018/053503 WO2019122777A1 (fr) | 2017-12-22 | 2018-12-21 | Composition cosmétique comprenant un extrait de caesalpinia spinosa, un extrait de kappaphycus alvarezii, et un hydrolysat de fèves de theobroma cacao l |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021507917A JP2021507917A (ja) | 2021-02-25 |
JP7478662B2 true JP7478662B2 (ja) | 2024-05-07 |
Family
ID=61802139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020534847A Active JP7478662B2 (ja) | 2017-12-22 | 2018-12-21 | カエサルピニア・スピノサ抽出物、カッパフィカス・アルベレッチー抽出物およびテオブロマカカオl豆の加水分解物を含む化粧品組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230210751A1 (ja) |
EP (1) | EP3727320B1 (ja) |
JP (1) | JP7478662B2 (ja) |
KR (1) | KR20200127980A (ja) |
CN (1) | CN111655222A (ja) |
ES (1) | ES2920451T3 (ja) |
FR (1) | FR3075621B1 (ja) |
WO (1) | WO2019122777A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112472637A (zh) * | 2019-10-09 | 2021-03-12 | 广东丸美生物技术股份有限公司 | 一种含长心卡帕藻提取物的紧肤精华及其制备方法 |
FR3108037B1 (fr) * | 2020-03-10 | 2022-04-01 | Farevacare | Composition cosmétique ou dermatologique d’entretien du microbiome cutané |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016142767A1 (en) | 2015-03-09 | 2016-09-15 | Bioimmunizer Sagl | Anti-age composition comprising a combination of antioxidant agents in association with bifidobacteria and cell walls isolated from probiotics |
WO2017129792A1 (fr) | 2016-01-29 | 2017-08-03 | Societe Industrielle Limousine D'application Biologique | Agent cosmetique tenseur et/ou filmogene constitue par des galactomannanes et des galactanes sulfates reticules |
WO2017129780A1 (fr) | 2016-01-29 | 2017-08-03 | Societe Industrielle Limousine D'application Biologique | Agent cosmetique constitue par des galactomannanes obtenus a partir de caesalpinia spinosa et des galactanes sulfates reticules obtenus a partir de kappaphycus alvarezii |
WO2017157998A1 (fr) | 2016-03-16 | 2017-09-21 | ISP Investments LLC. | Hydrolysat peptidique et osidique des fèves de cacao, compositions cosmetiques le comprenant et leurs utilisations cosmétiques |
WO2017173244A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Topical composition for reducing pathogen binding |
CN107397714A (zh) | 2017-07-19 | 2017-11-28 | 广东丸美生物技术股份有限公司 | 具有抗蓝光污染和淡化细纹功效的精华乳及其制备与应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0411670A (pt) * | 2003-06-20 | 2006-08-08 | Noveon Ip Holdings Corp | método para preparar hidrocolóides de galactomanana, hidrocolóide de galactomanana, composição, uso do hidrocolóide de galactomanana, produto para cuidado pessoal, produto para cuidado da saúde ou produto tópico para cuidado da saúde, produto para cuidados domésticos, produto institucional e industrial, e, método para purificar hicrocolóides de galactomanana |
US10786465B2 (en) | 2015-07-27 | 2020-09-29 | The Texas A&M University System | Polymer/copolymer nanoparticles conjugated to gambogic acid |
-
2017
- 2017-12-22 FR FR1763141A patent/FR3075621B1/fr active Active
-
2018
- 2018-12-21 WO PCT/FR2018/053503 patent/WO2019122777A1/fr unknown
- 2018-12-21 KR KR1020207021294A patent/KR20200127980A/ko not_active Application Discontinuation
- 2018-12-21 US US16/956,060 patent/US20230210751A1/en active Pending
- 2018-12-21 CN CN201880086435.9A patent/CN111655222A/zh active Pending
- 2018-12-21 JP JP2020534847A patent/JP7478662B2/ja active Active
- 2018-12-21 ES ES18842793T patent/ES2920451T3/es active Active
- 2018-12-21 EP EP18842793.4A patent/EP3727320B1/fr active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016142767A1 (en) | 2015-03-09 | 2016-09-15 | Bioimmunizer Sagl | Anti-age composition comprising a combination of antioxidant agents in association with bifidobacteria and cell walls isolated from probiotics |
WO2017129792A1 (fr) | 2016-01-29 | 2017-08-03 | Societe Industrielle Limousine D'application Biologique | Agent cosmetique tenseur et/ou filmogene constitue par des galactomannanes et des galactanes sulfates reticules |
WO2017129780A1 (fr) | 2016-01-29 | 2017-08-03 | Societe Industrielle Limousine D'application Biologique | Agent cosmetique constitue par des galactomannanes obtenus a partir de caesalpinia spinosa et des galactanes sulfates reticules obtenus a partir de kappaphycus alvarezii |
WO2017157998A1 (fr) | 2016-03-16 | 2017-09-21 | ISP Investments LLC. | Hydrolysat peptidique et osidique des fèves de cacao, compositions cosmetiques le comprenant et leurs utilisations cosmétiques |
WO2017173244A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Topical composition for reducing pathogen binding |
CN107397714A (zh) | 2017-07-19 | 2017-11-28 | 广东丸美生物技术股份有限公司 | 具有抗蓝光污染和淡化细纹功效的精华乳及其制备与应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2021507917A (ja) | 2021-02-25 |
WO2019122777A1 (fr) | 2019-06-27 |
FR3075621B1 (fr) | 2020-01-17 |
CN111655222A (zh) | 2020-09-11 |
EP3727320A1 (fr) | 2020-10-28 |
ES2920451T3 (es) | 2022-08-04 |
KR20200127980A (ko) | 2020-11-11 |
EP3727320B1 (fr) | 2022-04-06 |
FR3075621A1 (fr) | 2019-06-28 |
US20230210751A1 (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7479284B2 (ja) | カエサルピニア・スピノサ抽出物、カッパフィカス・アルベレッチー抽出物、少なくとも一つのプレバイオティクスおよびプロバイオティクスを含む化粧品組成物 | |
ES2947484T3 (es) | Composiciones que comprenden una cepa bacteriana Lactobacillus paracasei y ácido hialurónico y uso de las mismas para el tratamiento de la piel | |
JP6912772B2 (ja) | ヒアルロン酸産生促進剤およびこれを配合した化粧料 | |
KR20100101328A (ko) | 보습용 화장료 조성물 | |
JP7478662B2 (ja) | カエサルピニア・スピノサ抽出物、カッパフィカス・アルベレッチー抽出物およびテオブロマカカオl豆の加水分解物を含む化粧品組成物 | |
JP7457650B2 (ja) | テオブロマカカオl豆の加水分解物、少なくとも一つのプレバイオティクスおよびプロバイオティクスの含むメイクアップ組成物 | |
WO2022013897A1 (en) | Dermatological composition for rebalancing the skin, for increasing its hydration and elasticity and for reducing dynamic disorders | |
KR102367528B1 (ko) | 해조류 추출물을 유효성분으로 포함하는 화장료 조성물 | |
JP2004210653A (ja) | 皮膚外用剤 | |
JP6909569B2 (ja) | 肌質改善剤 | |
WO2019122778A1 (fr) | Composition cosmétique pour le traitement de la peau grasse | |
JP6805399B2 (ja) | 植物性乳酸菌を含むスキンケア剤 | |
JP6089163B1 (ja) | 美容組成物 | |
KR102360897B1 (ko) | 파라크레스 함유 콜라겐 메이크업 화장료 조성물 | |
RU2803052C1 (ru) | Способ получения жидкого косметического средства для ухода за кожей лица и тела с экстрактами из микроводорослей | |
RU2780260C1 (ru) | Средство косметического использования для кожи | |
FR3075620A1 (fr) | Composition cosmetique pour le traitement de la peau grasse | |
TW202231262A (zh) | 來自結構化水介質的發酵物與包含彼之化妝品組合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211214 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211214 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230609 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230919 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240314 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240422 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7478662 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |